Abstract Background Coronavirus disease 2019 (COVID-19) is caused by Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, previously named 2019-nCov), a novel …

Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …

Background Hematopoietic stem cell transplant (HSCT) recipients are at increased risk of
mortality and morbidity with coronavirus disease 2019 (COVID‐19) due to severe immune …

Background Many patients with COVID-19 have been treated with plasma containing anti-
SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent …

Background We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1–2 inhibitor,
for the treatment of patients admitted to hospital with COVID-19. Methods This randomised …

Introduction: Subjects with lung cancer were shown to present a variety of immune
abnormalities including cellular immune dysfunction, cytokine alterations, and antigen …

Background Casirivimab and imdevimab are non-competing monoclonal antibodies that
bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike …

Background Azithromycin has been proposed as a treatment for COVID-19 on the basis of
its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin …

The relative efficacy of autologous hematopoietic cell transplant (auto-HCT) vs chimeric
antigen receptor T-cell (CAR-T) therapy in patients with diffuse large B-cell lymphoma …

Chimeric antigen receptor (CAR) T cell therapy is changing the paradigm in hematologic
malignancies, but disparities in access exist in the real-world setting. Efforts to address and …